HC Wainwright Has Positive Estimate for TRDA Q2 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Stock analysts at HC Wainwright lifted their Q2 2026 EPS estimates for shares of Entrada Therapeutics in a report issued on Friday, May 8th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.19) per share for the quarter, up from their prior estimate of ($1.30). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($4.22) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.33) EPS, Q1 2027 earnings at ($0.79) EPS, Q2 2027 earnings at ($0.71) EPS, Q3 2027 earnings at ($0.78) EPS, Q4 2027 earnings at ($0.86) EPS and FY2027 earnings at ($3.14) EPS.

A number of other equities research analysts have also weighed in on TRDA. Roth Mkm set a $10.00 price objective on shares of Entrada Therapeutics in a report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Oppenheimer lifted their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Monday, April 6th. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Cantor Fitzgerald started coverage on shares of Entrada Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.25.

Entrada Therapeutics Stock Performance

Shares of TRDA opened at $7.00 on Tuesday. The firm has a market cap of $271.74 million, a price-to-earnings ratio of -1.75 and a beta of -0.09. Entrada Therapeutics has a fifty-two week low of $4.93 and a fifty-two week high of $16.45. The firm has a 50 day moving average price of $12.60 and a 200-day moving average price of $10.90.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 48.56%.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 15,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at approximately $3,044,354.04. The trade was a 7.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kory James Wentworth sold 11,388 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total transaction of $148,271.76. Following the transaction, the chief financial officer directly owned 121,510 shares in the company, valued at approximately $1,582,060.20. The trade was a 8.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 82,882 shares of company stock valued at $1,169,103. 9.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its position in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares during the period. Wellington Management Group LLP increased its position in Entrada Therapeutics by 9.5% during the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock valued at $10,740,000 after purchasing an additional 90,339 shares during the period. Millennium Management LLC grew its position in shares of Entrada Therapeutics by 391.2% in the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after buying an additional 666,287 shares during the period. Geode Capital Management LLC grew its position in shares of Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after buying an additional 42,479 shares during the period. Finally, State Street Corp grew its position in shares of Entrada Therapeutics by 2.0% in the 4th quarter. State Street Corp now owns 508,789 shares of the company’s stock worth $5,230,000 after buying an additional 10,174 shares during the period. 86.39% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright modestly raised its EPS forecasts for several periods, including Q2 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026 and FY2027, suggesting a slightly better earnings outlook for Entrada Therapeutics.
• Neutral Sentiment: HC Wainwright kept a Neutral rating on Entrada Therapeutics, indicating analysts are not yet ready to turn more constructive despite the small estimate changes.
• Neutral Sentiment: The company remains deeply unprofitable in analyst forecasts, with expected EPS losses continuing through 2026 and 2027, which limits enthusiasm for the shares.
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims on behalf of Entrada Therapeutics shareholders, a headline that can add legal overhang and pressure the stock. Article Title
• Negative Sentiment: Short-interest data showed no meaningful short positioning, offering little evidence of bullish conviction and suggesting the recent move may be more sentiment-driven than fundamentals-driven.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.